. 2022 Feb 18;7(8):7155–7171. doi: 10.1021/acsomega.1c06836

Table 3. Kinase Inhibitory Assay of the Newly Synthesized Derivatives 5–7 in Comparison with Erlotinib and AZD9291 against EGFR^WT and Mutant EGFR^T790M^a.

	IC₅₀ (mean ± SEM) (μM)
compound no.	EGFR^WT	EGFR^T790M
erlotinib	0.09 ± 0.05	0.55 ± 0.10
AZD9291	0.52 ± 0.03	0.03 ± 0.01
5a	0.25 ± 0.01	0.17 ± 0.05
5b	0.22 ± 0.15	0.13 ± 0.11
5c	0.24 ± 0.30	0.14 ± 0.50
6a	0.18 ± 0.10	0.12 ± 0.18
6b	0.08 ± 0.05	0.09 ± 0.01
6c	0.15 ± 0.02	0.13 ± 0.07
7	0.22 ± 0.05	0.18 ± 0.11

IC₅₀: compound concentration required to inhibit the enzymes’ activities by 50%; SEM: standard error mean; each value is the mean of three independent values.

Table 3. Kinase Inhibitory Assay of the Newly Synthesized Derivatives 5–7 in Comparison with Erlotinib and AZD9291 against EGFRWT and Mutant EGFRT790Ma.

Table 3. Kinase Inhibitory Assay of the Newly Synthesized Derivatives 5–7 in Comparison with Erlotinib and AZD9291 against EGFR^WT and Mutant EGFR^T790M^a.